Price$0.95+0.03 (+3.01%)
01:30 PM05:00 PM
News · 26 weeks60-23%
2026-01-042026-06-28
Mix3890d
- Insider15(39%)
- Other13(34%)
- SEC Filings8(21%)
- Earnings2(5%)
Latest news
25 items- INSIDERGC & Corp. Secretary Lapointe Christian sold $14,469 worth of shares (15,588 units at $0.93), decreasing direct ownership by 1% to 1,182,429 units (SEC Form 4) to satisfy tax liability4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERChief Financial Officer Keyes Jeffry R. sold $7,642 worth of shares (8,233 units at $0.93), decreasing direct ownership by 0.48% to 1,724,349 units (SEC Form 4) (tax withholding)4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERChief Product Officer Vieceli John S. sold $28,053 worth of shares (30,223 units at $0.93), decreasing direct ownership by 3% to 1,140,434 units (SEC Form 4) (withholding obligation)4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERPresident & CEO Hawkins Jeffrey Alan sold $20,997 worth of shares (22,621 units at $0.93), decreasing direct ownership by 0.61% to 3,669,802 units (SEC Form 4) (for tax liability)4 - Quantum-Si Inc (0001816431) (Issuer)
- SECSEC Form 144 filed by Quantum-Si Incorporated144 - Quantum-Si Inc (0001816431) (Subject)
- SECSEC Form 144 filed by Quantum-Si Incorporated144 - Quantum-Si Inc (0001816431) (Subject)
- SECQuantum-Si Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Quantum-Si Inc (0001816431) (Filer)
- PRQuantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 134,141 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).The 2023 Inducement Plan is used exclusively for the grant of equity awards to in
- SECSEC Form 25-NSE filed by Quantum-Si Incorporated25-NSE - Quantum-Si Inc (0001816431) (Subject)
- PRQuantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced a partnership with Cell Signaling Technology ("CST") to advance and validate next-generation protein sequencing and analysis of post-translational modifications ("PTM") on the Proteus™ single-molecule protein sequencing platform. The partnership will focus on integrating CST's PTM detection and immunoaffinity enrichment expertise with Quantum-Si's Proteus workflows to enable site-resolved detection and quantitation of proteins and PTMs for research applications. CST is a leading supplier of high-quality re
- PRQuantum-Si Announces the Expansion of the Proteus™ RoadshowMulti-City Roadshow is Driving Awareness of Proteus and Developing Customer Funnel for Commercial Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced the expansion of a roadshow designed to accelerate the education of the market on its Proteus platform and applications for protein sequencing. The roadshow includes information about the Proteus platform and application focus as well as data on applications for protein sequencing utilizing the Company's first-generation Platinum® Pro instrument. During the second quarter of 2026, the roads
- SECSEC Form SD filed by Quantum-Si IncorporatedSD - Quantum-Si Inc (0001816431) (Filer)
- INSIDERSEC Form 4 filed by Director Jafri Amir4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Director Makes Brigid4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Director Kenny John P.4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Director Dowdy Paula4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Director Fattori Ruth A4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Director Rothberg Jonathan M4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Director Kummeth Charles R.4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Director Mendel Scott4 - Quantum-Si Inc (0001816431) (Issuer)
- INSIDERSEC Form 4 filed by Director Rakin Kevin4 - Quantum-Si Inc (0001816431) (Issuer)
- SECQuantum-Si Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Quantum-Si Inc (0001816431) (Filer)
- PRQuantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 427,636 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards t
- SECSEC Form 10-Q filed by Quantum-Si Incorporated10-Q - Quantum-Si Inc (0001816431) (Filer)
- SECQuantum-Si Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Quantum-Si Inc (0001816431) (Filer)
QSI FAQ
7 questionsWhat does Quantum-Si Incorporated do?
Quantum-Si incorporated operates first next-generation protein sequencing and genomics platform for healthcare industries. It offers a single molecule detection solution to decode the molecules of life, including sample preparation, single molecule, massively parallel, and protein identification. The company's technology has the applications in proteomics, single cell, transcriptomics, genomics, metabolomics, and drug testing and screening fields. The company is based in Guilford, Connecticut. Quantum-Si incorporated is a subsidiary of 4Catalyzer Corporation.Where does QSI stock trade?
Quantum-Si Incorporated (QSI) is listed on NASDAQ.What sector and industry is QSI in?
Quantum-Si Incorporated operates in the Industrials sector, Industrial Machinery/Components industry.When did Quantum-Si Incorporated go public?
Quantum-Si Incorporated (QSI) completed its IPO in 2020.What are analysts saying about QSI?
Quantum-Si Incorporated has had 4 recent analyst actions on file. The most recent action was from Alliance Global Partners: Buy with a $375.00 price target on 2025-02-07.What companies are similar to QSI?
Notable peers in the same industry include ASML (ASML Holding N.V. New York Registry Shares), LRCX (Lam Research Corporation), TMO (Thermo Fisher Scientific Inc), DE (Deere & Company), ETN (Eaton Corporation PLC). Compare QSI side-by-side with any of them on Quantisnow.How can I track QSI on Quantisnow?
Quantisnow aggregates Quantum-Si Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QSI to receive live email and push alerts on every new disclosure.